Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 121 to 127 of 127 results for bacterial infections

  1. Rehabilitation for chronic neurological disorders including acquired brain injury (NG252)

    This guideline covers rehabilitation in all settings for children, young people and adults with a chronic neurological disorder, neurological impairment or disabling neurological symptoms due to acquired brain injury, acquired spinal cord injury, acquired peripheral nerve disorder, functional neurological disorder or progressive neurological disease.

  2. Boston Keratoprosthesis Type I for corneal blindness (MIB91)

    NICE has developed a medtech innovation briefing (MIB) on Boston Keratoprosthesis Type I for corneal blindness .

  3. The SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional changes in people with or at risk of developing glaucoma (MIB14)

    NICE has developed a Medtech Innovation Briefing (MIB) on the SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional

  4. Appeal panel membership

    The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.

  5. Four innovative tests for diagnosing UTIs could help in the fight against antimicrobial resistance

    NHS may use innovative tests which may help people with a urinary tract infection (UTI) receive the correct course of antibiotics more quickly.

  6. New guidance recommends transplant with good bacteria taken from poo

    Up to 500 people each year could be treated using faecal microbiota transplant for multiple recurrences of Clostridium difficile infections.

  7. NICE recommends genetic test to prevent newborn babies going deaf

    A genetic test to establish if a newborn baby is vulnerable to deafness if treated with a commonly used antibiotic has been recommended by NICE in final guidance.